

Supplementary materials

Systematic disease-agnostic identification of therapeutically actionable targets using the genetics of human plasma proteins

Authors

Mohd Anisul Karim^{*1,2}, Bruno Ariano^{1,2}, Jeremy Schwartzentruber^{1,2}, Juan Maria Roldan-Romero^{2,3}, Edward Mountjoy^{1,2}, James Hayhurst^{2,3}, Annalisa Buniello^{2,3}, Elmutaz Shaikho Elhaj Mohammed^{4, 5,6}, Miguel Carmona^{2,3}, Michael V Holmes^{5,6}, Chloe Robins⁷, Praveen Surendran⁸, Stephen Haddad⁹, Robert A Scott⁸, Andrew R. Leach^{2,3}, David Ochoa^{2,3}, Joseph Maranville⁴, Ellen M. McDonagh^{2,3}, Ian Dunham^{†1,2,3}, Maya Ghoussaini^{†*1,2}

Affiliations

1. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
2. Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
3. European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
4. Bristol-Myers Squibb, Cambridge, MA 02142, United States
5. 23andMe Inc., Sunnyvale, CA, USA
6. MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
7. GlaxoSmithKline Inc., Upper Providence, PA, US
8. GlaxoSmithKline Inc., Stevenage, UK
9. GlaxoSmithKline Inc., Cambridge, MA, US

[†]Joint Senior Authors


* To whom correspondence should be addressed:

Mohd Karim: anisulkarim@gmail.com


Maya Ghoussaini: mg29@sanger.ac.uk

Supplementary Figure 1: Effect estimate correlation plots between GSMR beta and MR-Egger/Weighted Median beta.

MR-Egger




Weighted Median




Supplementary Figure 2 : Use of Protein-protein interactions to expand the spectrum of druggable targets


Approach




Selected examples



Supplementary Figure 3: Trans-colocalization between IBD and ALPI at *FUT2*



Supplementary Figure 4: Forest plot showing the directionally opposing associations of asthma and IBD with different genetically predicted higher plasma proteins



Supplementary Figure 5: Difference between effect estimates of cis- and trans-pQTLs

